Possibilities of insulin glargine (Lantus ®) use for treatment of type 2 diabetes mellitus in the outpatient endocrinology services: an analysis of the register LAUREL

One way to glycemic control improvement in patients with type 1 and type 2 diabetes mellitus (CD) is the creation and introduction of new insulin preparations with improved pharmacokinetic and pharmacodynamic properties. Since 2005, in daily clinical practice long-acting analog of insulin Lantus (insulin glargine) became a regular used. The Lantus® administtration as a basal insulin can significantly improve glycemic control in patients with type 1 diabetes and type 2 diabetes not only in the short term treatment, but in long-term care. Clinical effectiveness and advantages of Lantus ® have been demonstrated in many studies, in most of whom insulin glargine was compared with NPH insulin. However, registers, allowing exploring and evaluating the use of the drug in the daily lives of large groups of patients, provide the most valuable information about the drugs from a clinical point of view. The data for LAUREL (LAntus Utilization in REal Life) register, whose main goal was to evaluate the effectiveness of insulin glargine in patients with type 2 diabetes, are presented. Register was created based on database of Russian clinics with the participation of 366 endocrinologists. The results of register showed the benefits of treatment of patients with type 2 diabetes with insulin glargine (Lantus) with available titration algorithms. Using Lantus ® in type 2 diabetes can improve glycemic control and reduce the frequency of hypoglycemic states in real clinical practice.

insulin-independent diabetes, Insulin glargine, glycated hemoglobin, hypoglycemic conditions, LAUREL Register